Amgen: Thrombocytopenia trials

The registry lists 20 Thrombocytopenia studies with Amgen as lead sponsor. 0 are open to participants now and 17 have results posted.

Phase 1 2Phase 2 8Phase 3 9Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)CompletedNCT02279173Phase 3Results posted
• Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric PatientsCompletedNCT01444417Phase 3Results posted
• Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving RomiplostimCompletedNCT01143038Phase 2Results posted
• A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia PurpuraCompletedNCT01071954Phase 3Results posted
• Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)CompletedNCT00907478Phase 4Results posted
• Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)CompletedNCT00614523Phase 2Results posted
• Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric SubjectsCompletedNCT00515203Phase 1/2Results posted
• An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITPCompletedNCT00508820Phase 3Results posted
• Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)CompletedNCT00472290Not applicableResults posted
• Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)CompletedNCT00454857Results posted
• A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving RevlimidCompletedNCT00418665Phase 2Results posted
• Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic PurpuraCompletedNCT00415532Phase 3Results posted
• Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00413283Phase 2Results posted
• Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating AgentsCompletedNCT00321711Phase 2Results posted
• Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)CompletedNCT00303472Phase 2Results posted
• A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With LymphomaCompletedNCT00283439Phase 1/2Results posted
• Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)CompletedNCT00116688Phase 3Results posted
• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.WithdrawnNCT03343847Phase 3
• AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to SplenectomyCompletedNCT00102336Phase 3
• AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to SplenectomyCompletedNCT00102323Phase 3